Skip to main content
Erschienen in: Angiogenesis 1/2024

01.08.2023 | Original Paper

VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients

verfasst von: Aurélien Philippe, Sven Günther, Jeanne Rancic, Pauline Cavagna, Bertrand Renaud, Nicolas Gendron, Elie Mousseaux, Thông Hua-Huy, Guillaume Reverdito, Benjamin Planquette, Olivier Sanchez, Pascale Gaussem, Dominique Salmon, Jean-Luc Diehl, David M. Smadja

Erschienen in: Angiogenesis | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Long COVID, also known as post-acute sequelae of COVID-19 (PASC), is characterized by persistent clinical symptoms following COVID-19.

Objective

To correlate biomarkers of endothelial dysfunction with persistent clinical symptoms and pulmonary function defects at distance from COVID-19.

Methods

Consecutive patients with long COVID-19 suspicion were enrolled. A panel of endothelial biomarkers was measured in each patient during clinical evaluation and pulmonary function test (PFT).

Results

The study included 137 PASC patients, mostly male (68%), with a median age of 55 years. A total of 194 PFTs were performed between months 3 and 24 after an episode of SARS-CoV-2 infection. We compared biomarkers evaluated in PASC patients with 20 healthy volunteers (HVs) and acute hospitalized COVID-19 patients (n = 88). The study found that angiogenesis-related biomarkers and von Willebrand factor (VWF) levels were increased in PASC patients compared to HVs without increased inflammatory or platelet activation markers. Moreover, VEGF-A and VWF were associated with persistent lung CT scan lesions and impaired diffusing capacity of the lungs for carbon monoxide (DLCO) measurement. By employing a Cox proportional hazards model adjusted for age, sex, and body mass index, we further confirmed the accuracy of VEGF-A and VWF. Following adjustment, VEGF-A emerged as the most significant predictive factor associated with persistent lung CT scan lesions and impaired DLCO measurement.

Conclusion

VEGF-A is a relevant predictive factor for DLCO impairment and radiological sequelae in PASC. Beyond being a biomarker, we hypothesize that the persistence of angiogenic disorders may contribute to long COVID symptoms.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV (2022) WHO clinical case definition working group on post-COVID-19 condition. a clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22(4):e102-7PubMedCrossRef Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV (2022) WHO clinical case definition working group on post-COVID-19 condition. a clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22(4):e102-7PubMedCrossRef
3.
Zurück zum Zitat Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M et al (2022) Post-acute COVID-19 syndrome. Eur Respir Rev Off J Eur Respir Soc 31(163):210185CrossRef Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M et al (2022) Post-acute COVID-19 syndrome. Eur Respir Rev Off J Eur Respir Soc 31(163):210185CrossRef
4.
Zurück zum Zitat Carfì A, Bernabei R, Landi F (2020) Gemelli against COVID-19 Post-acute care study group. persistent symptoms in patients after acute COVID-19. JAMA 324(6):603–5PubMedPubMedCentralCrossRef Carfì A, Bernabei R, Landi F (2020) Gemelli against COVID-19 Post-acute care study group. persistent symptoms in patients after acute COVID-19. JAMA 324(6):603–5PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y et al (2021) Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 27(1):89–95 Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y et al (2021) Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 27(1):89–95
6.
Zurück zum Zitat Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM (2022) Lifelines corona research initiative persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet Lond Engl 400(10350):452–61CrossRef Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM (2022) Lifelines corona research initiative persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet Lond Engl 400(10350):452–61CrossRef
7.
Zurück zum Zitat Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y et al (2021) 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet Lond Engl 398(10302):747–758CrossRef Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y et al (2021) 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet Lond Engl 398(10302):747–758CrossRef
8.
Zurück zum Zitat Huang L, Li X, Gu X, Zhang H, Ren L, Guo L et al (2022) Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 10(9):863–876PubMedPubMedCentralCrossRef Huang L, Li X, Gu X, Zhang H, Ren L, Guo L et al (2022) Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 10(9):863–876PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C et al (2022) Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328(16):1604–1615PubMedCentralCrossRef Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C et al (2022) Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328(16):1604–1615PubMedCentralCrossRef
10.
Zurück zum Zitat Mateu L, Tebe C, Loste C, Santos JR, Lladós G, López C, et al. Determinants of the Onset and Prognosis of the Post-COVID-19 Condition: A 2-Year Prospective Cohort Study [Internet]. SSRN; 2023. Retrieved July 13, 2023, from https://www.ssrn.com/abstract=4505315 Mateu L, Tebe C, Loste C, Santos JR, Lladós G, López C, et al. Determinants of the Onset and Prognosis of the Post-COVID-19 Condition: A 2-Year Prospective Cohort Study [Internet]. SSRN; 2023. Retrieved July 13, 2023, from https://​www.​ssrn.​com/​abstract=​4505315
12.
Zurück zum Zitat Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G et al (2023) Persistent Circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis Off Publ Infect Dis Soc Am 76(3):e487–e490CrossRef Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G et al (2023) Persistent Circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis Off Publ Infect Dis Soc Am 76(3):e487–e490CrossRef
13.
Zurück zum Zitat Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Cepinskas G et al (2023) Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning. Mol Med 29(1):26PubMedPubMedCentralCrossRef Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Cepinskas G et al (2023) Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning. Mol Med 29(1):26PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Gyöngyösi M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, da Costa Martins P et al (2023) Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on cellular biology of the heart and myocardial and pericardial diseases. Cardiovasc Res 119(2):336–56PubMedCrossRef Gyöngyösi M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, da Costa Martins P et al (2023) Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on cellular biology of the heart and myocardial and pericardial diseases. Cardiovasc Res 119(2):336–56PubMedCrossRef
15.
Zurück zum Zitat Chioh FW, Fong SW, Young BE, Wu KX, Siau A, Krishnan S et al (2021) Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife 10:e64909PubMedPubMedCentralCrossRef Chioh FW, Fong SW, Young BE, Wu KX, Siau A, Krishnan S et al (2021) Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife 10:e64909PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383(2):120–128PubMedPubMedCentralCrossRef Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383(2):120–128PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Smadja DM, Mentzer SJ, Fontenay M, Laffan MA, Ackermann M, Helms J et al (2021) COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis 24(4):755–788PubMedPubMedCentralCrossRef Smadja DM, Mentzer SJ, Fontenay M, Laffan MA, Ackermann M, Helms J et al (2021) COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis 24(4):755–788PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N et al (2021) Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 24(3):505–517PubMedPubMedCentralCrossRef Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N et al (2021) Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 24(3):505–517PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Werlein C, Ackermann M, Stark H, Shah HR, Tzankov A, Haslbauer JD et al (2022) Inflammation and vascular remodeling in COVID-19 hearts. Angiogenesis 12:1–16 Werlein C, Ackermann M, Stark H, Shah HR, Tzankov A, Haslbauer JD et al (2022) Inflammation and vascular remodeling in COVID-19 hearts. Angiogenesis 12:1–16
20.
Zurück zum Zitat Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruest M et al (2021) Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality. J Thromb Haemost JTH 19(7):1823–1830PubMedCrossRef Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruest M et al (2021) Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality. J Thromb Haemost JTH 19(7):1823–1830PubMedCrossRef
22.
Zurück zum Zitat Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E et al (2021) Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost JTH 19(10):2546–2553PubMedCrossRef Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E et al (2021) Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost JTH 19(10):2546–2553PubMedCrossRef
23.
Zurück zum Zitat Fogarty H, Ward SE, Townsend L, Karampini E, Elliott S, Conlon N et al (2022) Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost 20(10):2429–2438PubMedPubMedCentralCrossRef Fogarty H, Ward SE, Townsend L, Karampini E, Elliott S, Conlon N et al (2022) Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost 20(10):2429–2438PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al (2012) Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 40(6):1324–1343PubMedPubMedCentralCrossRef Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al (2012) Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 40(6):1324–1343PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW et al (2017) Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J 50(3):1700010PubMedCrossRef Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW et al (2017) Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J 50(3):1700010PubMedCrossRef
26.
Zurück zum Zitat ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1; 166(1):111–7 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1; 166(1):111–7
27.
Zurück zum Zitat Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158(5 Pt 1):1384–1387PubMedCrossRef Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158(5 Pt 1):1384–1387PubMedCrossRef
28.
Zurück zum Zitat Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N et al (2020) Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 295(3):200463PubMedCrossRef Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N et al (2020) Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 295(3):200463PubMedCrossRef
29.
Zurück zum Zitat Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X et al (2020) Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 296(2):E55-64PubMedCrossRef Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X et al (2020) Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 296(2):E55-64PubMedCrossRef
30.
Zurück zum Zitat Guerin CL, Guyonnet L, Goudot G, Revets D, Konstantinou M, Chipont A et al (2021) Multidimensional proteomic approach of endothelial progenitors demonstrate expression of KDR restricted to CD19 Cells. Stem Cell Rev Rep 17(2):639–651PubMedCrossRef Guerin CL, Guyonnet L, Goudot G, Revets D, Konstantinou M, Chipont A et al (2021) Multidimensional proteomic approach of endothelial progenitors demonstrate expression of KDR restricted to CD19 Cells. Stem Cell Rev Rep 17(2):639–651PubMedCrossRef
31.
Zurück zum Zitat Dudley AC, Griffioen AW (2023) Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis 15:1–35 Dudley AC, Griffioen AW (2023) Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis 15:1–35
32.
Zurück zum Zitat Ackermann M, Kamp JC, Werlein C, Walsh CL, Stark H, Prade V et al (2022) The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling. EBioMedicine 4(85):104296CrossRef Ackermann M, Kamp JC, Werlein C, Walsh CL, Stark H, Prade V et al (2022) The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling. EBioMedicine 4(85):104296CrossRef
33.
Zurück zum Zitat Kamp JC, Werlein C, Plucinski EKJ, Neubert L, Welte T, Lee PD et al (2023) Novel insight into pulmonary fibrosis and long COVID. Am J Respir Crit Care Med 207(8):1105–1107PubMedPubMedCentralCrossRef Kamp JC, Werlein C, Plucinski EKJ, Neubert L, Welte T, Lee PD et al (2023) Novel insight into pulmonary fibrosis and long COVID. Am J Respir Crit Care Med 207(8):1105–1107PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Barratt S, Medford AR, Millar AB (2014) Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome. Respir Int Rev Thorac Dis 87(4):329–342 Barratt S, Medford AR, Millar AB (2014) Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome. Respir Int Rev Thorac Dis 87(4):329–342
35.
Zurück zum Zitat Miao H, Qiu F, Zhu L, Jiang B, Yuan Y, Huang B et al (2021) Novel angiogenesis strategy to ameliorate pulmonary hypertension. J Thorac Cardiovasc Surg 161(6):e417–e434PubMedCrossRef Miao H, Qiu F, Zhu L, Jiang B, Yuan Y, Huang B et al (2021) Novel angiogenesis strategy to ameliorate pulmonary hypertension. J Thorac Cardiovasc Surg 161(6):e417–e434PubMedCrossRef
36.
Zurück zum Zitat Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Maître B et al (2000) Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. effect of prostacyclin therapy. Am J Respir Crit Care Med 162:1493–9PubMedCrossRef Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Maître B et al (2000) Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. effect of prostacyclin therapy. Am J Respir Crit Care Med 162:1493–9PubMedCrossRef
37.
Zurück zum Zitat Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S (1998) Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 18(6):768–776PubMedCrossRef Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S (1998) Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 18(6):768–776PubMedCrossRef
38.
Zurück zum Zitat Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S et al (2009) Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 119(3):374–381PubMedCrossRef Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S et al (2009) Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 119(3):374–381PubMedCrossRef
39.
Zurück zum Zitat Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y et al (2013) Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med 34(5):714–724PubMedCrossRef Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y et al (2013) Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med 34(5):714–724PubMedCrossRef
40.
Zurück zum Zitat Papaioannou AI, Kostikas K, Kollia P, Gourgoulianis KI (2006) Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res 7(1):128PubMedPubMedCentralCrossRef Papaioannou AI, Kostikas K, Kollia P, Gourgoulianis KI (2006) Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res 7(1):128PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Smadja DM, Nunes H, Juvin K, Bertil S, Valeyre D, Gaussem P et al (2014) Increase in both angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis. Pathol Biol (Paris) 62(6):391–394PubMedCrossRef Smadja DM, Nunes H, Juvin K, Bertil S, Valeyre D, Gaussem P et al (2014) Increase in both angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis. Pathol Biol (Paris) 62(6):391–394PubMedCrossRef
42.
Zurück zum Zitat Fukihara J, Kondoh Y (2016) Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med 10(12):1247–1254PubMedCrossRef Fukihara J, Kondoh Y (2016) Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med 10(12):1247–1254PubMedCrossRef
43.
Zurück zum Zitat Alfadda AA, Rafiullah M, Alkhowaiter M, Alotaibi N, Alzahrani M, Binkhamis K et al (2022) Clinical and biochemical characteristics of people experiencing post-coronavirus disease 2019-related symptoms: a prospective follow-up investigation. Front Med 9:1067082CrossRef Alfadda AA, Rafiullah M, Alkhowaiter M, Alotaibi N, Alzahrani M, Binkhamis K et al (2022) Clinical and biochemical characteristics of people experiencing post-coronavirus disease 2019-related symptoms: a prospective follow-up investigation. Front Med 9:1067082CrossRef
44.
Zurück zum Zitat Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Martin C et al (2022) Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med 28(1):122PubMedPubMedCentralCrossRef Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Martin C et al (2022) Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med 28(1):122PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A et al (2021) Immune-based prediction of COVID-19 severity and Chronicity decoded using machine learning. Front Immunol 28(12):700782CrossRef Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A et al (2021) Immune-based prediction of COVID-19 severity and Chronicity decoded using machine learning. Front Immunol 28(12):700782CrossRef
46.
Zurück zum Zitat Patterson BK, Yogendra R, Guevara-Coto J, Mora-Rodriguez RA, Osgood E, Bream J et al (2023) Case series: maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Front Med 10:1122529CrossRef Patterson BK, Yogendra R, Guevara-Coto J, Mora-Rodriguez RA, Osgood E, Bream J et al (2023) Case series: maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Front Med 10:1122529CrossRef
47.
Zurück zum Zitat Gupta A, Konnova A, Smet M, Berkell M, Savoldi A, Morra M et al (2023) Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. J Clin Invest 133(6):e166032PubMedPubMedCentralCrossRef Gupta A, Konnova A, Smet M, Berkell M, Savoldi A, Morra M et al (2023) Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. J Clin Invest 133(6):e166032PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Vojdani A, Vojdani E, Saidara E, Maes M (2023) Persistent SARS-CoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses 15(2):400PubMedPubMedCentralCrossRef Vojdani A, Vojdani E, Saidara E, Maes M (2023) Persistent SARS-CoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses 15(2):400PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Osiaevi I, Schulze A, Evers G, Harmening K, Vink H, Kümpers P et al (2023) Persistent capillary rarefication in long COVID syndrome. Angiogenesis 26(1):53–61PubMedCrossRef Osiaevi I, Schulze A, Evers G, Harmening K, Vink H, Kümpers P et al (2023) Persistent capillary rarefication in long COVID syndrome. Angiogenesis 26(1):53–61PubMedCrossRef
50.
Zurück zum Zitat Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169(11):1203–1208PubMedCrossRef Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169(11):1203–1208PubMedCrossRef
51.
Zurück zum Zitat Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R et al (2021) Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? insights from TUN-EndCOV study. Front Cardiovasc Med 8:745758PubMedPubMedCentralCrossRef Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R et al (2021) Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? insights from TUN-EndCOV study. Front Cardiovasc Med 8:745758PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Charfeddine S, Ibnhadjamor H, Jdidi J, Torjmen S, Kraiem S, Bahloul A et al (2022) Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study. Front Cardiovasc Med 9:866113PubMedPubMedCentralCrossRef Charfeddine S, Ibnhadjamor H, Jdidi J, Torjmen S, Kraiem S, Bahloul A et al (2022) Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study. Front Cardiovasc Med 9:866113PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Willems LH, Nagy M, Ten Cate H, Spronk HMH, Groh LA, Leentjens J et al (2022) Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res 209:106–114PubMedCrossRef Willems LH, Nagy M, Ten Cate H, Spronk HMH, Groh LA, Leentjens J et al (2022) Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res 209:106–114PubMedCrossRef
54.
Zurück zum Zitat Willems LH, Jacobs LMC, Groh LA, Ten Cate H, Spronk HMH, Wilson-Storey B et al (2023) Vascular function, systemic inflammation, and coagulation activation 18 months after COVID-19 infection: an observational cohort study. J Clin Med 12(4):1413PubMedPubMedCentralCrossRef Willems LH, Jacobs LMC, Groh LA, Ten Cate H, Spronk HMH, Wilson-Storey B et al (2023) Vascular function, systemic inflammation, and coagulation activation 18 months after COVID-19 infection: an observational cohort study. J Clin Med 12(4):1413PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Fan BE, Wong SW, Sum CLL, Lim GH, Leung BP, Tan CW et al (2022) Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: assessing the long-term outcomes in COVID-19 patients. Am J Hematol 97(7):915–923PubMedPubMedCentralCrossRef Fan BE, Wong SW, Sum CLL, Lim GH, Leung BP, Tan CW et al (2022) Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: assessing the long-term outcomes in COVID-19 patients. Am J Hematol 97(7):915–923PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Philippe A, Gendron N, Bory O, Beauvais A, Mirault T, Planquette B et al (2021) Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance. Angiogenesis 24(3):407–411PubMedPubMedCentralCrossRef Philippe A, Gendron N, Bory O, Beauvais A, Mirault T, Planquette B et al (2021) Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance. Angiogenesis 24(3):407–411PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Constantinescu-Bercu A, Kessler A, de Groot R, Dragunaite B, Heightman M, Hillman T et al (2023) Analysis of thrombogenicity under flow reveals new insights into the prothrombotic state of patients with post-COVID syndrome. J Thromb Haemost 21(1):94–100PubMedCrossRef Constantinescu-Bercu A, Kessler A, de Groot R, Dragunaite B, Heightman M, Hillman T et al (2023) Analysis of thrombogenicity under flow reveals new insights into the prothrombotic state of patients with post-COVID syndrome. J Thromb Haemost 21(1):94–100PubMedCrossRef
58.
Zurück zum Zitat Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A et al (2022) Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv 6(13):4041–4048PubMedPubMedCentralCrossRef Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A et al (2022) Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv 6(13):4041–4048PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Lorenzi O, Frieden M, Villemin P, Fournier M, Foti M, Vischer UM (2008) Protein kinase C-delta mediates von Willebrand factor secretion from endothelial cells in response to vascular endothelial growth factor (VEGF) but not histamine. J Thromb Haemost 6(11):1962–1969PubMedCrossRef Lorenzi O, Frieden M, Villemin P, Fournier M, Foti M, Vischer UM (2008) Protein kinase C-delta mediates von Willebrand factor secretion from endothelial cells in response to vascular endothelial growth factor (VEGF) but not histamine. J Thromb Haemost 6(11):1962–1969PubMedCrossRef
60.
Zurück zum Zitat Yang X, Jian Sun H, Rong Li Z, Zhang H, Jun Yang W, Ni B et al (2015) Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer 15:80PubMedPubMedCentralCrossRef Yang X, Jian Sun H, Rong Li Z, Zhang H, Jun Yang W, Ni B et al (2015) Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer 15:80PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Matsushita K, Yamakuchi M, Morrell CN, Ozaki M, O’Rourke B, Irani K et al (2005) Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood 105(1):207–214PubMedCrossRef Matsushita K, Yamakuchi M, Morrell CN, Ozaki M, O’Rourke B, Irani K et al (2005) Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood 105(1):207–214PubMedCrossRef
62.
Zurück zum Zitat Geindreau M, Ghiringhelli F, Bruchard M (2021) Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci 22(9):4871PubMedPubMedCentralCrossRef Geindreau M, Ghiringhelli F, Bruchard M (2021) Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci 22(9):4871PubMedPubMedCentralCrossRef
63.
Metadaten
Titel
VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients
verfasst von
Aurélien Philippe
Sven Günther
Jeanne Rancic
Pauline Cavagna
Bertrand Renaud
Nicolas Gendron
Elie Mousseaux
Thông Hua-Huy
Guillaume Reverdito
Benjamin Planquette
Olivier Sanchez
Pascale Gaussem
Dominique Salmon
Jean-Luc Diehl
David M. Smadja
Publikationsdatum
01.08.2023
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 1/2024
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-023-09890-9

Weitere Artikel der Ausgabe 1/2024

Angiogenesis 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

"Limited stage" SCLC: Konsolidierung schenkt Lebensjahre

14.06.2024 ASCO 2024 Kongressbericht

Standardtherapie bei einem inoperablen kleinzelligen Lungenkarzinom im Stadium I-III (LS-SCLC) ist die Radiochemotherapie. Eine anschließende Konsolidierung mit Durvalumab kann das mediane Überleben um fast zwei Jahre verlängern.

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Degenerierte Bioklappe: Ist Reoperation oder TAVI hier die bessere Option?

13.06.2024 TAVI Nachrichten

Im Fall eines Bioprothesen-Versagens nach Aortenklappenersatz kann ein notwendiger Revisionseingriff heute operativ oder kathetergestützt als Valve-in-Valve-TAVI vorgenommen werden. Eine Beobachtungsstudie lieferte neue Daten zum Vergleich beider Optionen.

Fortgeschrittenes Ovarial-Ca.: Unverdächtige Lymphknoten entfernen?

13.06.2024 ASCO 2024 Kongressbericht

Beim fortgeschrittenen Ovarialkarzinom und klinisch verdächtigen Lymphknoten in der Debulking-Op. ist die abdominale retroperitoneale Lymphadenektomie (RPL) Standard. Ohne verdächtige Lymphknoten ist der Nutzen fraglich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.